Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
- Conditions
- Interventions
- First Posted Date
- 2011-05-18
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT01355289
- Locations
- 🇺🇸
Health Care Consultants, Los Angeles, California, United States
🇺🇸Metropolitan Research, Fairfax, Virginia, United States
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-05-18
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01355302
- Locations
- 🇺🇸
Boca Raton Clinical Research Associates, Inc, Plantation, Florida, United States
🇺🇸Robert H. Lurie Comprenhensive Cancer Center of Northwestern University, Chicago, Illinois, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
- First Posted Date
- 2011-05-04
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT01347645
Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT01335009
- Locations
- 🇺🇸
University of Iowa Hospital, Iowa City, Iowa, United States
🇺🇸Atlantic Health, Morristown, New Jersey, United States
🇺🇸New York University Cancer Institute, New York, New York, United States
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT01332266
Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT01327872
- Locations
- 🇳🇱
PRA Early Development Services, Zuidlaren, Netherlands
Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia
- Conditions
- Interventions
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 357
- Registration Number
- NCT01327859
Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 452
- Registration Number
- NCT01327885
Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT01328249
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center ,Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
- First Posted Date
- 2011-03-23
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 392
- Registration Number
- NCT01321554
- Locations
- 🇬🇧
Facility 2, Manchester, United Kingdom
🇬🇧Facility 3, London, United Kingdom
🇬🇧Facility 1, Sutton, United Kingdom